ImmuPharma Patent Filing Sends Small-Cap Shares Soaring as AIM Market Sees Mixed Gains

ImmuPharma shares surged after the company filed a patent covering its lead drug, P140, and an accompanying diagnostic test, sending the biotech’s stock sharply higher and energising the small-cap segment of London’s AIM market.

The shares have climbed about 572 percent over the past month, with a dramatic take-off beginning on Sept. 1 after the patent application was lodged. Over the most recent week, ImmuPharma finished 138 percent higher as investors responded to details that suggest P140 could act as an "immunormaliser"—a therapy intended to correct an overactive immune system without suppressing natural defenses. The patent, if granted, could secure up to 20 years of protection and covers both the therapy and a diagnostic aimed at patients with a recently defined "Type M" immune disorder, potentially speeding diagnosis and widening the drug’s applicability.

Chief Executive Tim McCarthy described the filing as "a game changer," saying it strengthened the group’s negotiating position with potential partners. Company and broker commentary has framed the combination of a therapeutic and a companion diagnostic as a way to sharpen trial results by identifying suitable patient populations, and to broaden potential use across as many as 50 autoimmune conditions. Analysts and investors caution that the development pathway remains challenging, but the prospect of a treatment that restores immune balance without the side effects of conventional immunosuppressants has driven substantial speculative buying.

The movement in ImmuPharma helped buoy a generally muted week on AIM. The AIM All-Share index ended the five trading days after the rally up 0.5 percent from a recent strong rally level of 769.74, while London blue-chips outperformed, rising about 1.3 percent over the same period.

Elsewhere on AIM, a number of small and mid-cap stocks recorded large percentage changes on company-specific news or investor reappraisal. 80 Mile jumped roughly 50 percent after the terms of Pelican Acquisition Corporation’s merger implied a $92 million valuation for the company’s retained 30 percent stake in the Jameson hydrocarbon project in Greenland, a move that investors interpreted as increasing the value of the group ahead of a planned drilling campaign.

Resource-focused Rockfire Resources rose about 48 percent after confirming that diamond drilling had commenced at its Molaoi zinc project in Greece. The company said a 10,000-metre programme is under way to upgrade resources and to investigate germanium potential, with management promising a steady flow of updates through early 2026 as work progresses.

Video technology group SEEEN advanced around 24 percent after reporting revenue of $3.04 million for 2024, up 48 percent year on year, and saying growth had accelerated into 2025. The company said it had reached monthly cashflow breakeven and flagged a potential $3.5 million contract, which investors viewed as evidence of improving commercial traction.

Not all movers were gains. Cancer-diagnostic developer ANGLE tumbled roughly 57 percent following interim results that were poorly received by the market. On Friday the company notified investors that founder and long-serving Chief Executive Andrew Newland and Finance Director Ian Griffiths would step down from the board following discussions with a major shareholder.

Payments group Finseta fell about 37 percent after trimming its full-year growth guidance, citing weaker-than-expected trading in US dollar-denominated revenue. The company reported first-half revenue up 16 percent to £5.9 million but said earnings were reduced as it invested in new initiatives intended to support medium-term expansion.

Shares of Distil, a premium spirits maker that attracted attention after greentech entrepreneur Graham Cooley built a stake, slid about 33 percent after a period of profit-taking. The stock had rallied roughly 130 percent over the prior six months and fell during the week on no new company-specific news.

Clinical-stage biotech Scancell drew attention after prelims that highlighted significant clinical progress in the past year and outlined an active programme of milestones. The company’s house broker, Panmure Liberum, reiterated a "buy" rating and a 32-pence target, compared with a recent share price around 8.45p, arguing that current levels already discount much of the risk. Scancell said it expects data from studies such as SCOPE and Modi-1, regulatory feedback, progress toward potential partnering for its iSCIB1+ programme and ongoing work on its GlyMab candidate over the next 18 months. Analysts cautioned that the route to registrational trials is expensive and will likely require additional funding, even as recent melanoma vaccine trial results in July have encouraged backers.

Market participants said the week’s moves reflect a combination of speculative interest in biotech patent and trial news, revaluation of exploration and resource plays ahead of drilling programmes, and profit-taking in richly run-up shares. The shifts underscore the high volatility in AIM’s small- and mid-cap universe, where company-specific catalysts can produce outsized daily and weekly moves.

For now, ImmuPharma’s filing has concentrated investor focus on the potential for a new class of immune therapies and the ways companion diagnostics may alter development pathways. Whether P140 can translate early promise into regulatory approvals, commercial partnerships and sustainable revenues remains to be seen, and analysts note that substantial clinical proof and additional financing would be required before that potential is realised.